Michael Salacz

2.0k total citations
20 papers, 469 citations indexed

About

Michael Salacz is a scholar working on Genetics, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Salacz has authored 20 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Salacz's work include Glioma Diagnosis and Treatment (11 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Research and Treatments (2 papers). Michael Salacz is often cited by papers focused on Glioma Diagnosis and Treatment (11 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer Research and Treatments (2 papers). Michael Salacz collaborates with scholars based in United States, Germany and Switzerland. Michael Salacz's co-authors include Peggy Ward‐Smith, David A. Reardon, Do Hyun Nam, Benoît Lhermitte, Danica Grujičić, James Perry, Monika E. Hegi, Maria Mazurkiewicz‐Bełdzińska, Martin Picard and Christine Hicking and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancers.

In The Last Decade

Michael Salacz

17 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Salacz United States 9 168 114 112 101 90 20 469
Timothy J. O’Brien United States 10 113 0.7× 68 0.6× 147 1.3× 120 1.2× 23 0.3× 14 372
Lindsey A. Olivere United States 8 52 0.3× 59 0.5× 131 1.2× 200 2.0× 79 0.9× 19 480
Julius Wehrle Germany 13 110 0.7× 157 1.4× 192 1.7× 87 0.9× 44 0.5× 29 411
Tamara New United States 13 189 1.1× 156 1.4× 452 4.0× 211 2.1× 99 1.1× 21 861
Kristian T. Schafernak United States 13 66 0.4× 55 0.5× 159 1.4× 116 1.1× 136 1.5× 41 550
Laura Bui United Kingdom 10 76 0.5× 81 0.7× 123 1.1× 81 0.8× 39 0.4× 32 426
Katherine Beaverson United States 14 82 0.5× 28 0.2× 192 1.7× 184 1.8× 80 0.9× 24 624
Karin Blakolmer United States 12 98 0.6× 201 1.8× 91 0.8× 92 0.9× 34 0.4× 20 628
Deva Sharma United States 13 231 1.4× 165 1.4× 102 0.9× 161 1.6× 52 0.6× 39 598
Monica Yu United States 6 70 0.4× 158 1.4× 411 3.7× 58 0.6× 28 0.3× 8 705

Countries citing papers authored by Michael Salacz

Since Specialization
Citations

This map shows the geographic impact of Michael Salacz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Salacz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Salacz more than expected).

Fields of papers citing papers by Michael Salacz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Salacz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Salacz. The network helps show where Michael Salacz may publish in the future.

Co-authorship network of co-authors of Michael Salacz

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Salacz. A scholar is included among the top collaborators of Michael Salacz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Salacz. Michael Salacz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barkhoudarian, Garni, Michael Badruddoja, Sajeel Chowdhary, et al.. (2023). An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology. 12(3). CNS102–CNS102. 4 indexed citations
2.
Kast, Richard E., Alex Alfieri, Hazem Assi, et al.. (2022). MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. Cancers. 14(10). 2563–2563. 9 indexed citations
3.
Powers, Benjamin, et al.. (2018). Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy. Journal of Oncology Pharmacy Practice. 25(7). 1784–1786. 6 indexed citations
4.
Kast, Richard E. & Michael Salacz. (2018). DIPG-30. A NEW TREATMENT OPPORTUNITY FOR DIPG: 5-ALA AND SONODYNAMIC AUGMENTED MEV IRRADIATION, THE ASAI PROTOCOL. Neuro-Oncology. 20(suppl_2). i55–i55.
5.
Zadeh, Gelareh, Tobias Walbert, James Perry, et al.. (2018). 10 Toca 5: Toca 511 combined with Toca FC versus standard of care in patients undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 45(S3). S2–S2.
6.
Salacz, Michael, et al.. (2017). Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. Surgical Neurology International. 8(1). 243–243. 2 indexed citations
7.
Salacz, Michael, Marc‐Eric Halatsch, Georg Karpel‐Massler, & Richard E. Kast. (2017). RARE-09. MINIMALLY TOXIC MULTIMODAL AND POLYPHARMACOLOGICAL THERAPY IN TREATMENT OF DIFFUSE MIDLINE GLIOMA. Neuro-Oncology. 19(suppl_6). vi213–vi213. 1 indexed citations
8.
Halatsch, Marc‐Eric, Michael Salacz, Bernd Schmitz, Georg Karpel‐Massler, & Richard E. Kast. (2017). EXTH-79. INITIAL EXPERIENCES WITH COMPASSIONATE-USE CUSP9v3/v4 FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19(suppl_6). vi90–vi90. 5 indexed citations
9.
Salacz, Michael, Richard E. Kast, Najmaldin Saki, et al.. (2016). Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen. OncoTargets and Therapy. 9. 2535–2535. 28 indexed citations
10.
Oronsky, Bryan, Jan Scicinski, Michelle M. Kim, et al.. (2016). Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules. 6(3). 32–32. 10 indexed citations
11.
12.
Salacz, Michael, et al.. (2011). Glioblastoma: Part I. Current state of affairs.. PubMed. 108(3). 187–94. 14 indexed citations
13.
Salacz, Michael, et al.. (2011). Glioblastoma. Part II: Future directions.. Missouri medicine. 108(4). 289–91. 5 indexed citations
14.
Ward‐Smith, Peggy, et al.. (2008). When a Family Member Has a Malignant Brain Tumor. Journal of Neuroscience Nursing. 40(2). 78–84. 63 indexed citations
15.
Salacz, Michael, Annick Desjardins, Jennifer A. Quinn, et al.. (2008). Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea. Journal of Clinical Oncology. 26(15_suppl). 2071–2071.
16.
Maron, Roman C., James J. Vredenburgh, Annick Desjardins, et al.. (2008). Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology. 26(15_suppl). 2074–2074. 12 indexed citations
17.
Salacz, Michael, Michael W. Lankiewicz, & David E. Weissman. (2007). Management of Thrombocytopenia in Bone Marrow Failure: A Review. Journal of Palliative Medicine. 10(1). 236–244. 10 indexed citations
18.
Arnold, Robert M., et al.. (2006). Cannabinoids in the Treatment of Symptoms in Cancer and AIDS #93: Megestrol Acetate for Cancer Anorexia/Cachexia #100. Journal of Palliative Medicine. 9(3). 802–804. 8 indexed citations
19.
Salacz, Michael & David E. Weissman. (2005). Controlled Sedation for Refractory Suffering: Part I. Journal of Palliative Medicine. 8(1). 136–138. 6 indexed citations
20.
Boylan, Brian, Hong Chen, Vipul Rathore, et al.. (2004). Anti-GPVI–associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRγ-chain complex from the human platelet surface. Blood. 104(5). 1350–1355. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy J. O’Brien Breakdown of academic impact, for papers by Lindsey A. Olivere Breakdown of academic impact, for papers by Julius Wehrle Breakdown of academic impact, for papers by Tamara New Breakdown of academic impact, for papers by Kristian T. Schafernak Breakdown of academic impact, for papers by Laura Bui Breakdown of academic impact, for papers by Katherine Beaverson Breakdown of academic impact, for papers by Karin Blakolmer Breakdown of academic impact, for papers by Deva Sharma Breakdown of academic impact, for papers by Monica Yu
Rankless by CCL
2026